The global allergy diagnostic market is expected to grow from USD 6.80 billion in 2025 to USD 10.77 billion by 2030, at a CAGR of 9.6%. Growth is driven by technological innovations such as multiplex immunoassays and molecular allergology, rising allergy incidence, and increasing awareness. North America leads the market, with major players including Thermo Fisher Scientific, Siemens Healthineers, and Danaher Corporation dominating the competitive landscape.

While broader markets sell off amid Iran conflict concerns, five stocks are outperforming their weak peer groups by demonstrating relative strength and solid fundamentals. These stocks span software, cybersecurity, healthcare, and telecom sectors, each showing earnings growth and operational discipline that justify their resilience.

The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

The global DNA read, write and edit market is projected to grow from $21.4 billion in 2024 to $67.7 billion by 2030 at a 21.2% CAGR, driven by expanding clinical applications of genome editing, genomic diagnostics demand, and CRISPR-based therapeutics investment. North America leads with 43.5% market share.

The global validation, calibration, and standardization market in life sciences is projected to grow from $2.7 billion in 2024 to $3.9 billion by 2030 at a 6.7% CAGR. Growth is driven by stringent regulatory requirements, the expansion of complex biologics and advanced therapy medicinal products (ATMPs), and digital transformation including AI-driven platforms and cloud-based compliance systems. North America leads with 40.5% market share.

The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.

The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

The global oncology biomarkers market is projected to grow from $17.3 billion in 2025 to $33.63 billion by 2030, with a CAGR of 14.3%. Growth is driven by rising cancer incidence, personalized oncology therapies, AI-driven biomarker discovery, liquid biopsy adoption, and early cancer detection focus. Key players include Roche, Novartis, and Thermo Fisher Scientific.

Major M&A activity continues with Estée Lauder in merger discussions with Puig ($40B), KKR acquiring Nothing Bundt Cakes ($2B+), and Amazon acquiring robotics firm Fauna. Other significant deals include Corebridge-Equitable Holdings merger ($22B), Merck's acquisition of Terns Pharmaceuticals ($6.7B), and Abbott closing its Exact Sciences deal ($21B). Several companies filed for bankruptcy including 23andMe and Applebee's franchisee NRPF.

The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.

The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.